Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

409.47 -6.78 (-1.63%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
67 68 Next >
Unpacking Q2 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q2, starting with Vertex... 
Via StockStory
Topics Artificial Intelligence
Healthcare Stocks Are at an Historic Low and a Turnaround Is on the Horizon
There is a "for sale" sign on the sector, and these two stocks look particularly attractive at their current levels. 
Via The Motley Fool
Topics Government Intellectual Property World Trade
My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years
Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of billions dollars in revenue. 
Via Benzinga
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy
From Vertex Pharmaceuticals
Via Business Wire
2 Growth Stocks to Buy and Hold Forever
Look beyond the recent headwinds these two have faced. 
Via The Motley Fool
Topics World Trade
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Screens as a Top Undervalued Stock with Strong Fundamentals
Vertex Pharmaceuticals (VRTX) is a strong value stock with high profitability, zero debt, and solid growth, trading at an attractive valuation within the biotech sector. 
Via Chartmill
Why This Biotech Company Could Be a Growth Stock Powerhouse
The stock has soared in the triple-digits over the past decade. 
Via The Motley Fool
1 Reason Wall Street Is Obsessed With Vertex Pharmaceuticals
Here's why you can't find a Wall Street analyst who will tell you to sell this stock. 
Via The Motley Fool
Topics Intellectual Property
3 Absurdly Cheap Stocks to Buy for the Long Haul
They trade at some incredibly low earnings multiples. 
Via The Motley Fool
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 15 Years
 
Via Benzinga
Vertex Scientists Awarded the 2025 Lasker~DeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Shows Strong Fundamentals and Technical Breakout Potential
Vertex Pharmaceuticals (VRTX) is a top growth stock with strong fundamentals, high profitability, and a technical setup hinting at a potential breakout for investors. 
Via Chartmill
Cathie Wood Goes Bargain Hunting: She Just Bought 2 Stocks That Wall Street Thinks Will Climb 50% and 190%
These companies are reaching key milestones. 
Via The Motley Fool
1 Safe-and-Steady Stock to Research Further and 2 We Turn Down
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. 
Via StockStory
Why This Biotech Company Could Be a Growth Stock Powerhouse
Recent developments aren't as devastating to the company's prospects as some might think. 
Via The Motley Fool
Demystifying Vertex Pharmaceuticals: Insights From 16 Analyst Reviews
 
Via Benzinga
Vertex Pharmaceuticals Inc (NASDAQ:VRTX): A Top GARP Stock with Strong Growth and Reasonable Valuation
Vertex Pharmaceuticals (VRTX) exemplifies the GARP strategy with strong growth, a reasonable valuation, high profitability, and a robust debt-free balance sheet. 
Via Chartmill
Tuesday's session: top gainers and losers in the S&P500 index
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Tuesday. 
Via Chartmill
Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years
 
Via Benzinga
3 No-Brainer Stocks to Buy Right Now
Investing in these pharmaceutical stocks is an easy decision. 
Via The Motley Fool
Topics World Trade
My 2 Favorite Stocks to Buy Right Now
Looking for good investing ideas? These two stocks could be huge winners for long-term investors. 
Via The Motley Fool
Topics Artificial Intelligence
Navigating the Currents: Top Sectors Primed for Growth in Q3 2025
The global economy is sailing into Q3 2025 with a blend of cautious optimism and persistent challenges. While a new tariff regime and elevated geopolitical tensions introduce elements of uncertainty,... 
Via MarketMinute
Topics Artificial Intelligence Economy Retirement
What's Driving the Market Sentiment Around Vertex Pharmaceuticals?
 
Via Benzinga
Vertex Pharmaceuticals Inc (NASDAQ:VRTX): A Prime Candidate for Value Investors
Vertex Pharmaceuticals (VRTX) is a top value stock with strong financials, high profitability, and impressive growth, trading below its biotech peers. 
Via Chartmill
This Magnificent S&P 500 Dividend Stock Is Down 18% -- Time to Buy?
It's been an unusually bad year for this drugmaker, but it's essential to look beyond that. 
Via The Motley Fool
Topics Law Enforcement Stocks
2 Beaten-Down Stocks With Incredible Upside Potential
These stocks should be able to rebound strongly. 
Via The Motley Fool
Vertex to Participate in Upcoming September Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
What's Wrong With Vertex Pharmaceuticals Stock?
Shares of the pharma company are down 17% in the past 12 months. 
Via The Motley Fool
2 Nasdaq 100 Stocks to Consider Right Now and 1 Facing Challenges
The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a winner - some are struggling with slowing... 
Via StockStory
Trump 2.0 At 200 Days: Palantir Surges, Tesla Slumps
Palantir leads all stocks in the S&P 500 with a stunning 160% gain in Trump's first 200 days. 
Via Benzinga
Topics Government Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
67 68 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.